Articles & Insights

The global animal regenerative therapies market is projected to more than double by 2032 — and horses are driving it. From the first FDA-tracked stem cell tendon therapy to nanotechnology joint gels that resolved lameness in 72% of horses, here's every major product launching right now and why equine medicine is becoming the proving ground for human longevity science.

An elite horse developed a joint infection weeks before the Olympics — the kind that kills 1 in 5 horses and ends most careers. Seven days of an experimental peptide treatment later, it competed on the world's biggest stage. Here's the science behind BIO-PLY, and why it matters far beyond the racetrack.

A San Francisco biotech has cleared two of three FDA requirements for a daily longevity pill for senior dogs — a drug that could add meaningful healthy years to your dog's life. The largest clinical trial in veterinary history is already underway. Here's where it stands.

Two weeks before the FDA decides the fate of BPC-157 and TB-500, the agency's own scientists have quietly complicated the story — their briefing documents raise real safety and data-quality concerns, even as political pressure pushes the other direction.

A San Francisco biotech just implanted the first cat with a slow-release GLP-1 device, and the internet immediately nicknamed it Meowzempic. Here's what the trial actually involves — and why it's nothing like giving your cat your own Ozempic.

Dog owners are posting BPC-157 and TB-500 recovery videos for torn ligaments all over social media. The clips are compelling — the evidence behind them is a lot thinner. Here's how to tell the difference.

The FDA just took the first formal step toward legalizing compounded BPC-157 and TB-500 — the two peptides most commonly used off-label in pets. Here's exactly what changed, what didn't, and what it means before you talk to your vet.